J&J Discontinues Gene Therapy Program for Geographic Atrophy After Phase 2b Readout
The inherited retinal disease (IRD) community is closely watching advancements in gene therapy, a field that holds immense promise for treating various forms of vision loss. News from pharmaceutical giant Johnson & Johnson (J&J) indicates a significant development in this space, as the company has decided to discontinue the development of its eye disease gene therapy, JNJ-1887, following a review of data from its Phase 2b clinical trial. This decision, announced on July 15, 2026, impacts a potential treatment for geographic atrophy, an advanced form of age-related macular degeneration (AMD).
Key Facts from the Announcement
J&J confirmed on July 15, 2026, that it has stopped the development of JNJ-1887. This decision came after assessing the topline data from the Phase 2b Parasol study. The Parasol trial was a sham-controlled clinical trial that evaluated JNJ-1887 for the treatment of geographic atrophy. J&J had acquired the asset, previously known as HMR59, in 2020 from Hemera Biosciences. The company had initiated the 305-subject Parasol trial in 2023. A J&J spokesperson stated that the development program for JNJ-1887 in geographic atrophy would be discontinued, adding that the company would apply learnings from this program to its early-stage pipeline in ophthalmology.
JNJ-1887 utilized an adeno-associated virus serotype 2 (AAV2) vector to express a soluble form of CD59. This naturally occurring protein inhibits the membrane attack complex, an immune effector implicated in AMD development and progression. The trial aimed to assess whether a single intravitreal injection of the gene therapy could reduce geographic atrophy lesions over 18 months.
What This Means for Patients and Families
For individuals and families affected by geographic atrophy and other inherited retinal diseases, news of a discontinued clinical trial can be disheartening. While JNJ-1887 was specifically targeting geographic atrophy, a condition distinct from many inherited retinal diseases, the broader field of gene therapy research is interconnected. Each trial, successful or not, contributes valuable knowledge to the scientific community. The discontinuation of JNJ-1887 highlights the significant challenges inherent in developing gene therapies for complex retinal conditions. However, J&J has indicated that it will use the insights gained from this program to inform its future ophthalmology research.
It is important to note that other companies are continuing to develop gene therapies for geographic atrophy, with some also focusing on the complement pathway but targeting different mechanisms. This ongoing research underscores the continued commitment within the biotech and pharmaceutical industries to find effective treatments for vision-threatening eye diseases.
Looking Ahead
While this particular gene therapy program will not move forward, the field of ophthalmology continues to be a dynamic area of research. The data and experiences from the Parasol study will contribute to the collective understanding of gene therapy delivery, complement biology, and the design of future clinical trials for retinal diseases. The IRD community can anticipate further developments as researchers and companies apply these learnings to advance new therapeutic candidates.